By: David Nicklaus Source: St. Louis Post-Dispatch Date: December 2, 2016 When RiverVest Venture Partners opened its doors in 2000, hopes were high that it would be an important funding source for St. Louis’ nascent biotechnology industry. RiverVest went on to be a highly successful venture capital firm, managing $290 million and demonstrating a knack […]
ST. LOUIS, MO (Nov. 30, 2016) – Life sciences venture capital firm RiverVest Venture Partners today announced the closing of Archer Seed Fund, L.P. at $15 million.
Long-term collaboration for US distribution of Tryton Side Branch Stent pending regulatory approval. DURHAM, NC – October 27, 2016 – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, and Cardinal Health, a global integrated healthcare services and products company, today announced that the companies have established a long-term strategic […]
ST. LOUIS, MO (Sept. 16, 2016) – Tioma Therapeutics, Inc., a RiverVest portfolio company developing therapies to treat solid and blood-based cancers, announced it has raised $86 million in Series A venture financing. The Series A financing included early investor RiverVest along with Novo Ventures, GlaxoSmithKline’s corporate venture arm S.R. One, Limited and new investors, Roche […]
Cleveland, OH, September. 15, 2016 — Securus Medical Group, Inc., a privately held medical device company, announced the closing of a $10 million Series C financing led by Boston Scientific Corporation. Boston Scientific joined with existing investors RiverVest Venture Partners, 3X5 Special Opportunity Fund, and the University of Michigan MINTS program, as well as another […]